Abstract

Albertsons Companies, Inc. will report quarterly results on October 13, 2026, Pre-MKt; this preview compiles the latest financial estimates, recent performance, and current institutional viewpoints on earnings momentum and segment dynamics.

Market Forecast

Consensus points to total revenue of 18.88 billion US dollars for the current quarter, an estimated year-over-year decline of 0.12%, with adjusted EPS projected at 0.33 (down 18.12% year over year) and EBIT near 0.31 billion US dollars (down 17.72% year over year). The company’s recent operational changes and merchandising initiatives frame the outlook for center-store categories and fresh, while forecast margin metrics for the quarter are not disclosed.

Within the main business, non-perishables are expected to anchor performance as promotion, pricing, and supply-chain execution are centralized to improve consistency and in-stock rates. Perishables present the strongest near-term potential for relative stability through local-market merchandising stewardship and shrink control; last quarter, perishables contributed 7.88 billion US dollars in revenue, and overall company revenue grew 0.24% year over year.

Last Quarter Review

Albertsons Companies, Inc. delivered last quarter revenue of 24.94 billion US dollars, a gross profit margin of 26.61%, GAAP net profit attributable to the parent of 84.70 million US dollars, a net profit margin of 0.34%, and adjusted EPS of 0.42, down 23.64% year over year.

A notable financial highlight was the strong quarter-on-quarter rebound in net profit, up 117.62%, supported by tighter expense control and improving merchandising execution. Main business contributions were led by non-perishables at 11.88 billion US dollars, perishables at 7.88 billion US dollars, pharmacy at 3.30 billion US dollars, fuel at 1.46 billion US dollars, and other at 0.41 million US dollars, while total company revenue grew 0.24% year over year.

Current Quarter Outlook

Main Business: Non-Perishables

Non-perishables remain the largest revenue contributor and the focal point of the company’s structural reset to improve pricing, promotions, and supplier engagement. The transition to a centralized enterprise team for center-store merchandising aims to streamline decision-making, consolidate vendor negotiations, and create clear accountability across pricing and promotional calendars. Last quarter’s non-perishables revenue of 11.88 billion US dollars underscores the scale and importance of this category to quarterly earnings.

The newly established regional structure—moving from 11 divisions to four regions—should facilitate faster execution of center-store strategies across local markets while maintaining a unified enterprise approach to assortment and promotions. This alignment can help mitigate fragmentation in pricing and reduce inefficiencies that historically weighed on margins and sales conversion. If in-stock rates and promotional cadence improve as intended, the non-perishables segment could support steadier EPS performance even as overall revenue is forecast to be down slightly year over year.

Most Promising Business: Perishables

Perishables, at 7.88 billion US dollars last quarter, are positioned to benefit from the company’s decision to keep fresh merchandising under local-market control, preserving the agility needed to address regional preferences and supply variability. Shrink reduction, procurement discipline in produce and meat, and more tailored local assortments can support margin resilience and traffic. These levers are especially relevant in quarters when center-store demand softens, enabling perishable categories to sustain trips with quality and freshness differentiation.

Operationally, tighter store-level execution—supported by the new regional model—can improve presentation standards, waste control, and promotional accuracy in perishables. These improvements tend to have outsized impact on perception of value and quality, which can lift basket composition even when consumers are cautious. The company’s fresh-first emphasis thus offers a defensive advantage in a slower spending environment; success here should contribute positively to EBIT trajectory despite the overall revenue decline projected for the quarter.

Key Stock Price Drivers This Quarter

Earnings trajectory relative to guidance and consensus will be the primary driver for the stock, with investors focusing on whether EPS at 0.33 and EBIT near 0.31 billion US dollars can be achieved amid soft top-line expectations. Execution of the “ACI Edge” restructuring and the regional operating model will be closely watched for early evidence of measurable merchandising and in-stock improvements, especially in center-store categories. Any quantified benefits—such as clearer cost savings, improved promotion efficiency, or lower shrink—could ease concerns about revenue pressure and support margin narratives.

Pharmacy dynamics will be another key variable, as reimbursement trends and federal drug price negotiations affect topline growth and profitability. Recent commentary highlights potential pressure as certain therapies receive broader coverage, which can reduce realized reimbursement; investors will parse script trends, mix, and margin disclosures carefully. Leadership changes—Cody Perdue appointed interim CFO effective October 1, 2026—may also factor into sentiment if updated guidance or capital allocation signals are provided; a steady transition with maintained financial discipline would favor the equity story.

Analyst Opinions

Bullish viewpoints form the majority of recent institutional commentary, with multiple firms arguing that the structural changes and valuation present an attractive setup despite near-term revenue pressure. Wells Fargo’s Edward Kelly maintained a Buy rating with an 18.00 US dollars price target, expressing confidence that operational initiatives can support improved merchandising consistency and stabilize earnings in the face of cautious consumer spending. BMO Capital’s Kelly Bania also kept a Buy rating with a 23.00 US dollars target, emphasizing the opportunity for execution improvements to drive better cost control and promotion effectiveness.

Telsey Advisory’s Joe Feldman reaffirmed a Buy rating with a 22.00 US dollars target, highlighting the potential for the new regional structure to tighten store-level execution and enhance center-store performance. RBC Capital Markets maintained an Outperform stance while lowering near-term estimates, noting that while visibility is limited and adjustments are required, the risk-reward at current levels appears favorable as the company advances its restructuring and merchandising changes. Collectively, these bullish views point to an expectation that the earnings drag from revenue softness can be mitigated by the reorganization and tighter operational controls, setting the stage for improving margin metrics over coming quarters.

The predominance of Buy recommendations contrasts with more cautious takes that focus on pharmacy headwinds and potential earnings downside; however, the majority position anticipates that the company’s operational reset will yield measurable benefits. Analysts in the bullish camp will look for confirmation in October 13, 2026 results—specifically, whether adjusted EPS meets the 0.33 expectation, EBIT lands near 0.31 billion US dollars, and center-store execution shows early progress. If the company can demonstrate that restructuring is translating into better promotions, in-stock performance, and moderated shrink, the equity story should gain support even with revenue down 0.12% year over year in the current quarter.